Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | Director · PRESIDENT AND CEO | October 06, 2026 | October 08, 2026 |
| QUEST DIAGNOSTICS INCDGX · Entity 2118 | Director | May 25, 2021 | May 25, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HALOZYME THERAPEUTICS, INC.
Report date October 06, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 767,780 |
Ending reported balance
After 2026-10-08 transaction · row 15
15 source rows · reconciled sequenceRow 1 · 2026-10-06 · Exercise / conversion · Acquired 20,000 · Balance 787,780 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. Row 2 · 2026-10-06 · Sale · Disposed 2,300 · Balance 785,480 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F2: Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.480 to $108.290. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 3 · 2026-10-06 · Sale · Disposed 6,000 · Balance 779,480 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F3: Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.530 to $109.520. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 4 · 2026-10-06 · Sale · Disposed 9,920 · Balance 769,560 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F4: Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.530 to $110.510. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 5 · 2026-10-06 · Sale · Disposed 1,780 · Balance 767,780 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F5: Represents a weighted average sales price per share. The shares were sold at prices ranging from $110.530 to $111.210. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 6 · 2026-10-07 · Exercise / conversion · Acquired 20,000 · Balance 787,780 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. Row 7 · 2026-10-07 · Sale · Disposed 8,600 · Balance 779,180 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F6: Represents a weighted average sales price per share. The shares were sold at prices ranging from $110.360 to $111.350. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 8 · 2026-10-07 · Sale · Disposed 10,300 · Balance 768,880 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F7: Represents a weighted average sales price per share. The shares were sold at prices ranging from $111.380 to $112.360. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 9 · 2026-10-07 · Sale · Disposed 900 · Balance 767,980 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F8: Represents a weighted average sales price per share. The shares were sold at prices ranging from $112.400 to $113.190. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 10 · 2026-10-07 · Sale · Disposed 200 · Balance 767,780 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F9: Represents a weighted average sales price per share. The shares were sold at prices ranging from $113.590 to $113.860. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 11 · 2026-10-08 · Exercise / conversion · Acquired 20,000 · Balance 787,780 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. Row 12 · 2026-10-08 · Sale · Disposed 4,810 · Balance 782,970 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F10: Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.480 to $108.475. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 13 · 2026-10-08 · Sale · Disposed 3,090 · Balance 779,880 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F11: Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.480 to $109.470. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 14 · 2026-10-08 · Sale · Disposed 11,900 · Balance 767,980 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F12: Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.510 to $110.500. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 15 · 2026-10-08 · Sale · Disposed 200 · Balance 767,780 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $18.41 · Expires 2028-02-14 | Direct | 61,552 |
Reported balance
After 2026-10-06 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-10-06 · Exercise / conversion · Disposed 20,000 · Balance 61,552 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F13: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $18.41 · Expires 2028-02-14 | Direct | 41,552 |
Reported balance
After 2026-10-07 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-10-07 · Exercise / conversion · Disposed 20,000 · Balance 41,552 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F13: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $18.41 · Expires 2028-02-14 | Direct | 21,552 |
Reported balance
After 2026-10-08 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2026-10-08 · Exercise / conversion · Disposed 20,000 · Balance 21,552 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F13: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028.
F2: Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.480 to $108.290. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.530 to $109.520. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4: Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.530 to $110.510. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5: Represents a weighted average sales price per share. The shares were sold at prices ranging from $110.530 to $111.210. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6: Represents a weighted average sales price per share. The shares were sold at prices ranging from $110.360 to $111.350. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F7: Represents a weighted average sales price per share. The shares were sold at prices ranging from $111.380 to $112.360. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F8: Represents a weighted average sales price per share. The shares were sold at prices ranging from $112.400 to $113.190. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F9: Represents a weighted average sales price per share. The shares were sold at prices ranging from $113.590 to $113.860. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F10: Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.480 to $108.475. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F11: Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.480 to $109.470. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F12: Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.510 to $110.500. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F13: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018.
QUEST DIAGNOSTICS INC
Report date May 25, 2021 · Filed May 25, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,260 |
Reported balance
After 2021-05-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-05-25 · Grant · Acquired 1,363 · Balance 6,260 F1: Represents an award of restricted share units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted share units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2022 Filed Feb 17, 2022 23:02 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 6,892 | $34.43 | $237,291.56 |
DisclosureSEC source: 0001179110-22-001391 · edgar.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 587,177 F1 · shares: The reported disposition of 6,892 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 23:02 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 13,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001391 · edgar.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594,069 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 00:27 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 28,729 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001199 · edgar.xml · derivative · entry 9 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,729 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F4 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 00:27 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 15,125 | $33.64 | $508,805.00 |
DisclosureSEC source: 0001179110-22-001199 · edgar.xml · nonDerivative · entry 6 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,977 F3 · shares: he reported disposition of 15,125 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 00:27 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 28,729 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001199 · edgar.xml · nonDerivative · entry 5 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 596,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 00:27 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 32,795 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001199 · edgar.xml · derivative · entry 8 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,794 Underlying: Common Stock · 32,795 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F4 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 00:27 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 17,266 | $34.20 | $590,497.20 |
DisclosureSEC source: 0001179110-22-001199 · edgar.xml · nonDerivative · entry 4 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 567,373 F2 · shares: The reported disposition of 17,266 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 00:27 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 32,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001199 · edgar.xml · nonDerivative · entry 3 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 584,639 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 00:27 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 31,282 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001199 · edgar.xml · derivative · entry 7 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,562 Underlying: Common Stock · 31,282 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F4 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 00:27 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 16,598 | $34.94 | $579,934.12 |
DisclosureSEC source: 0001179110-22-001199 · edgar.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 551,844 F1 · shares: The reported disposition of 16,598 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 00:27 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 31,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001199 · edgar.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2021 Filed Nov 8, 2021 23:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 50,000 | $14.66 Strike: $14.66 | $733,000.00 |
DisclosureSEC source: 0001179110-21-009952 · edgar.xml · derivative · entry 4 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 50,000 shares Expires 2024-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. F4 · derivative.exercise_date: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was January 6, 2014. Read SEC document |
| November 08, 2021 Filed Nov 8, 2021 23:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 12,225 | $40.42 | $494,122.28 |
DisclosureSEC source: 0001179110-21-009952 · edgar.xml · nonDerivative · entry 3 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 537,160 F1 · kind: The option exercise and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $40.25 to $40.63. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 08, 2021 Filed Nov 8, 2021 23:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 37,775 | $39.62 | $1,496,645.50 |
DisclosureSEC source: 0001179110-21-009952 · edgar.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 549,385 F1 · kind: The option exercise and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $39.25 to $40.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 08, 2021 Filed Nov 8, 2021 23:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 50,000 | $14.66 | $733,000.00 |
DisclosureSEC source: 0001179110-21-009952 · edgar.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 587,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. Read SEC document |
| October 04, 2021 Filed Oct 4, 2021 23:37 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 50,000 | $14.66 Strike: $14.66 | $733,000.00 |
DisclosureSEC source: 0001179110-21-009169 · edgar.xml · derivative · entry 4 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 50,000 shares Expires 2024-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. F4 · derivative.exercise_date: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was January 6, 2014. Read SEC document |
| October 04, 2021 Filed Oct 4, 2021 23:37 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 5,857 | $40.95 | $239,861.72 |
DisclosureSEC source: 0001179110-21-009169 · edgar.xml · nonDerivative · entry 3 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 537,160 F1 · kind: The option exercise and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $40.65 to $41.10. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 04, 2021 Filed Oct 4, 2021 23:37 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 44,143 | $39.97 | $1,764,528.14 |
DisclosureSEC source: 0001179110-21-009169 · edgar.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 543,017 F1 · kind: The option exercise and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $39.65 to $40.63. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 04, 2021 Filed Oct 4, 2021 23:37 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 50,000 | $14.66 | $733,000.00 |
DisclosureSEC source: 0001179110-21-009169 · edgar.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 587,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. Read SEC document |
| September 07, 2021 Filed Sep 7, 2021 21:46 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 50,000 | $14.66 Strike: $14.66 | $733,000.00 |
DisclosureSEC source: 0001179110-21-008665 · edgar.xml · derivative · entry 4 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 50,000 shares Expires 2024-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. F4 · derivative.exercise_date: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was January 6, 2014. Read SEC document |
| September 07, 2021 Filed Sep 7, 2021 21:46 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 6,560 | $42.98 | $281,942.24 |
DisclosureSEC source: 0001179110-21-008665 · edgar.xml · nonDerivative · entry 3 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 537,160 F1 · kind: The option exercise and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $42.93 to $43.17. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 07, 2021 Filed Sep 7, 2021 21:46 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 43,440 | $42.29 | $1,836,903.84 |
DisclosureSEC source: 0001179110-21-008665 · edgar.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 543,720 F1 · kind: The option exercise and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $41.90 to $42.87. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 07, 2021 Filed Sep 7, 2021 21:46 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 50,000 | $14.66 | $733,000.00 |
DisclosureSEC source: 0001179110-21-008665 · edgar.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 587,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 23:01 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 50,000 | $14.66 Strike: $14.66 | $733,000.00 |
DisclosureSEC source: 0001179110-21-008095 · edgar.xml · derivative · entry 8 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 50,000 shares Expires 2024-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. F7 · derivative.exercise_date: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was January 6, 2014. Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 23:01 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 1,048 | $46.11 | $48,323.28 |
DisclosureSEC source: 0001179110-21-008095 · edgar.xml · nonDerivative · entry 7 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 537,160 F1 · kind: The option exercise and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 23:01 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 500 | $44.91 | $22,454.00 |
DisclosureSEC source: 0001179110-21-008095 · edgar.xml · nonDerivative · entry 6 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 538,208 F1 · kind: The option exercise and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. F6 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $44.76 to $45.02. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 23:01 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 400 | $43.26 | $17,304.00 |
DisclosureSEC source: 0001179110-21-008095 · edgar.xml · nonDerivative · entry 5 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 538,708 F1 · kind: The option exercise and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. F5 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $43.17 to $43.33. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 23:01 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 1,000 | $42.64 | $42,640.00 |
DisclosureSEC source: 0001179110-21-008095 · edgar.xml · nonDerivative · entry 4 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 539,108 F1 · kind: The option exercise and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. F4 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $42.07 to $42.99. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 23:01 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 21,914 | $41.47 | $908,751.67 |
DisclosureSEC source: 0001179110-21-008095 · edgar.xml · nonDerivative · entry 3 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,108 F1 · kind: The option exercise and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $40.98 to $41.97. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 23:01 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 25,138 | $40.42 | $1,016,103.10 |
DisclosureSEC source: 0001179110-21-008095 · edgar.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 562,022 F1 · kind: The option exercise and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $39.92 to $40.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 23:01 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 50,000 | $14.66 | $733,000.00 |
DisclosureSEC source: 0001179110-21-008095 · edgar.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 587,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. Read SEC document |
| July 06, 2021 Filed Jul 6, 2021 22:09 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 50,000 | $14.66 Strike: $14.66 | $733,000.00 |
DisclosureSEC source: 0001179110-21-007396 · edgar.xml · derivative · entry 3 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 50,000 shares Expires 2024-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was January 6, 2014. Read SEC document |
| July 06, 2021 Filed Jul 6, 2021 22:09 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 50,000 | $45.97 | $2,298,650.00 |
DisclosureSEC source: 0001179110-21-007396 · edgar.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 537,160 F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $45.40 to $46.33. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 06, 2021 Filed Jul 6, 2021 22:09 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 50,000 | $14.66 | $733,000.00 |
DisclosureSEC source: 0001179110-21-007396 · edgar.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 587,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. Read SEC document |
| June 07, 2021 Filed Jun 7, 2021 22:53 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 50,000 | $14.66 Strike: $14.66 | $733,000.00 |
DisclosureSEC source: 0001179110-21-006466 · edgar.xml · derivative · entry 3 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 50,000 shares Expires 2024-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was January 6, 2014. Read SEC document |
| June 07, 2021 Filed Jun 7, 2021 22:53 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 50,000 | $39.66 | $1,982,950.00 |
DisclosureSEC source: 0001179110-21-006466 · edgar.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 537,160 F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $39.12 to $40.02. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 07, 2021 Filed Jun 7, 2021 22:53 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 50,000 | $14.66 | $733,000.00 |
DisclosureSEC source: 0001179110-21-006466 · edgar.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 587,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. Read SEC document |
| May 25, 2021 Filed May 25, 2021 20:41 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 1,363 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-21-000091 · wf-form4_162197523887689.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,260 F1 · security: Represents an award of restricted share units. Read SEC document |
| May 11, 2021 Filed May 11, 2021 22:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 50,000 | $14.66 Strike: $14.66 | $733,000.00 |
DisclosureSEC source: 0001179110-21-005214 · edgar.xml · derivative · entry 6 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 50,000 shares Expires 2024-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was January 6, 2014. Read SEC document |
| May 11, 2021 Filed May 11, 2021 22:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 1,066 | $44.84 | $47,802.64 |
DisclosureSEC source: 0001179110-21-005214 · edgar.xml · nonDerivative · entry 5 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 537,160 F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. F5 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $44.63 to $44.98. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 11, 2021 Filed May 11, 2021 22:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 3,956 | $44.11 | $174,479.38 |
DisclosureSEC source: 0001179110-21-005214 · edgar.xml · nonDerivative · entry 4 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 538,226 F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. F4 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $43.59 to $44.38. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 11, 2021 Filed May 11, 2021 22:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 36,522 | $43.05 | $1,572,235.58 |
DisclosureSEC source: 0001179110-21-005214 · edgar.xml · nonDerivative · entry 3 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 542,182 F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $42.57 to $43.50. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 11, 2021 Filed May 11, 2021 22:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 8,456 | $42.17 | $356,581.06 |
DisclosureSEC source: 0001179110-21-005214 · edgar.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 578,704 F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $41.56 to $42.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 11, 2021 Filed May 11, 2021 22:22 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 50,000 | $14.66 | $733,000.00 |
DisclosureSEC source: 0001179110-21-005214 · edgar.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 587,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. Read SEC document |
| April 05, 2021 Filed Apr 5, 2021 23:51 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 50,000 | $14.66 Strike: $14.66 | $733,000.00 |
DisclosureSEC source: 0001179110-21-004215 · edgar.xml · derivative · entry 3 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 50,000 shares Expires 2024-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was January 6, 2014. Read SEC document |
| April 05, 2021 Filed Apr 5, 2021 23:51 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 50,000 | $42.55 | $2,127,250.00 |
DisclosureSEC source: 0001179110-21-004215 · edgar.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 537,160 F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $42.159 to $42.83. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 05, 2021 Filed Apr 5, 2021 23:51 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 50,000 | $14.66 | $733,000.00 |
DisclosureSEC source: 0001179110-21-004215 · edgar.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 587,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 01:03 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 50,000 | $14.66 Strike: $14.66 | $733,000.00 |
DisclosureSEC source: 0001179110-21-002485 · edgar.xml · derivative · entry 4 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,000 Underlying: Common Stock · 50,000 shares Expires 2024-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was January 6, 2014. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 01:03 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 33,890 | $46.48 | $1,575,112.31 |
DisclosureSEC source: 0001179110-21-002485 · edgar.xml · nonDerivative · entry 3 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 537,160 F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $46.13 to $46.84. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 01:03 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 16,110 | $45.58 | $734,342.13 |
DisclosureSEC source: 0001179110-21-002485 · edgar.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 571,050 F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $45.12 to $46.11. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.